GSK bails on $4.2bn partnership with Merck on cancer drugGlaxoSmithKline has ended its collaboration with Germany’s Merck KGaA’s cancer treatment bintrafusp alfa, after a trio of failed Share XGSK bails on $4.2bn partnership with Merck on cancer drughttps://pharmaphorum.com/news/gsk-bails-on-4-2bn-partnership-with-merck-on-cancer-drug/
Third strike for GSK/Merck as bintrafusp alfa flubs againGlaxoSmithKline’s big gamble on Merck KGaA’s bintrafusp alfa has gone from bad to worse, after the drug failed Share XThird strike for GSK/Merck as bintrafusp alfa flubs againhttps://pharmaphorum.com/news/third-strike-for-gsk-merck-cancer-alliance-as-bintrafusp-alfa-flubs-again/
GSK’s big-ticket cancer alliance with Merck KGaA stumbles againMerck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a Share XGSK’s big-ticket cancer alliance with Merck KGaA stumbles againhttps://pharmaphorum.com/news/gsks-big-ticket-cancer-alliance-with-merck-kgaa-hits-another-hurdle/
GSK/Merck’s hopeful bintrafusp alfa fails in key lung cancer trialGlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after Share XGSK/Merck’s hopeful bintrafusp alfa fails in key lung cancer trialhttps://pharmaphorum.com/news/gsk-merck-cos-hopeful-bintrafusp-alfa-fails-in-key-lung-cancer-trial/
